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M I C R O B I O T A
Disturbed gut microbiota and bile homeostasis in 
Giardia-infected mice contributes to metabolic 
dysregulation and growth impairment
Ambre Riba1, Kasra Hassani2, Alesia Walker3, Niels van Best1,4, Dunja von Zeschwitz1, 
Teresa Anslinger1, Nina Sillner3,5, Stefanie Rosenhain6, Daniel Eibach7, Oumou Maiga-Ascofaré8, 
Ulrike Rolle-Kampczyk9, Marijana Basic10, Anne Binz11, Sabine Mocek12, Beate Sodeik11, 
Rudolf Bauerfeind13, Antje Mohs14, Christian Trautwein14, Fabian Kiessling6,15,16, Jürgen May7, 
Martin Klingenspor12, Felix Gremse6,17,18, Philippe Schmitt-Kopplin3,5,19, André Bleich10, 
Natalia Torow1, Martin von Bergen9,20, Mathias W. Hornef1*
Although infection with the human enteropathogen Giardia lamblia causes self-limited diarrhea in adults, infant 
populations in endemic areas experience persistent pathogen carriage in the absence of diarrhea. The persistence 
of this protozoan parasite in infants has been associated with reduced weight gain and linear growth (height-for-age). 
The mechanisms that support persistent infection and determine the different disease outcomes in the infant 
host are incompletely understood. Using a neonatal mouse model of persistent G. lamblia infection, we demon-
strate that G. lamblia induced bile secretion and used the bile constituent phosphatidylcholine as a substrate for 
parasite growth. In addition, we show that G. lamblia infection altered the enteric microbiota composition, lead-
ing to enhanced bile acid deconjugation and increased expression of fibroblast growth factor 15. This resulted in 
elevated energy expenditure and dysregulated lipid metabolism with reduced adipose tissue, body weight 
gain, and growth in the infected mice. Our results indicate that this enteropathogen’s modulation of bile acid 
metabolism and lipid metabolism in the neonatal mouse host led to an altered body composition, suggesting 
how G. lamblia infection could contribute to growth restriction in infants in endemic areas.
INTRODUCTION
Giardia lamblia, also named Giardia intestinalis or Giardia duode-
nalis, is a major cause of diarrheal disease worldwide, estimated to 
lead to about 280 million annual cases (1). Oral administration to 
study volunteers, outbreak descriptions, and disease occurrence in 
travelers to endemic areas have highlighted G. lamblia’s pathogenic 
potential in causing episodes of diarrhea, vomiting, abdominal 
pain, and anorexia (2, 3). For most patients, the disease is acute and 
self-limiting, although some individuals experience prolonged diar-
rhea with malabsorption (3, 4). In notable contrast, several longitu-
dinal studies have shown that G. lamblia infection in children in 
endemic areas is not associated with acute diarrheal disease (5–8). 
The presence of G. lamblia, at least in some areas, may even diminish 
the likelihood of having acute moderate to severe diarrhea (9–11). 
Initial G. lamblia infection in early infancy may rather be associated 
with persistent (>14 days) disease (8). Three recent prospective hu-
man studies identified the presence of G. lamblia in infant stool 
samples as an independent risk factor for reduced linear growth 
(7,  10,  12). In particular, exposure to G. lamblia during an early 
neonatal window was associated with reduced weight-for-height 
and weight-for-age (13). An unsafe water supply and insufficient 
sanitation support parasite transmission and may explain the high 
prevalence of G. lamblia in infant stool samples and rapid reinfec-
tions after drug-induced cure (10, 11, 14, 15).
Despite epidemiological evidence for an association between per-
sistent or recurrent G. lamblia infection and reduced linear growth 
in infants, a causal relationship has not been established and the 
underlying mechanisms remain incompletely understood (16–18). 
G. lamblia infection is associated with increased intestinal permea-
bility (10). Alterations in the mucosal permeability of the gut have 
been associated with impaired growth in later life and might thus 
represent a causal link (19). However, a multitude of possible con-
founders including malnutrition and immune impairment, phylo-
genetic differences of G. lamblia strains, coinfections with other 
enteropathogens, and undernutrition-associated changes in the gut 
microbiota composition may critically influence infection suscepti-
bility and disease outcomes, complicating the interpretation of the 
reported epidemiological findings in humans. Furthermore, pre-
clinical models indicate not only that G. lamblia coinfection can 
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promote malnutrition and growth impairment but also that malnu-
trition aggravates the course of G. lamblia infection (20–22).
Here, we used a mouse model of persistent G. lamblia infection 
after trophozoite administration to healthy neonatal mice (22–24). 
Persistent infection led to reduced body weight gain and linear 
growth impairment in the absence of an impaired gut mucosal 
barrier, thus mimicking the phenotype of endemic G. lamblia infec-
tion in human infants. We deployed transcriptional profiling, 
microbiome and metabolome analysis, and whole-body imaging to 
investigate the underlying mechanism of pathogen persistence in 
the mouse small intestine after neonatal host infection and meta-
bolic dysregulation during persistent infection.
RESULTS
Age-dependent susceptibility to persistent  
G. lamblia infection
The high carriage rate of G. lamblia among children in endemic 
areas and the unexplained association with reduced weight gain and 
growth prompted us to comparatively investigate the consequences 
of oral G. lamblia infection in mice of different ages (7, 8, 10). Con-
sistent with previous reports, healthy 4-week-old adult animals 
infected with G. lamblia trophozoites cleared the infection within 
2 to 3 weeks (25, 26). Only the administration of G. lamblia cysts 
(H3 strain) was reported to induce prolonged infection in healthy 
adult animals (21). In notable contrast, mice infected as neonates 
exhibited persistent carriage with stable parasite counts and pro-
longed antigen shedding (P < 0.05) (Fig. 1A and fig. S1A). Mice in-
fected at the age of 2 weeks exhibited an intermediate phenotype, 
defining the postnatal window as the age of enhanced vulnerability 
(fig. S1B). Prolonged monitoring revealed that C57BL/6J mice in-
fected as neonates (3-day-old mice) remained G. lamblia positive 
for more than 20 weeks, at which point they started to spontaneously 
clear the infection (Fig. 1B).
We next characterized the parasite’s organ tropism and the 
host’s mucosal response to infection. Histological and ultrastruc-
tural analysis illustrated dense colonization of the proximal small 
intestine and intimate interaction between the protozoan and the 
intestinal epithelium’s apical membrane at both 1 and 4 weeks 
post-infection (p.i.) (Fig.  1,  C  and  D). Trophozoite counts and 
quantitative polymerase chain reaction (PCR) readily detected 
G. lamblia in the small intestine’s luminal contents during the 
course of the infection with maximum abundance in the proximal 
part of the small intestine, as reported in humans (Fig. 1, E and F). 
Despite the parasite’s continuous presence, however, we observed 
neither inflammatory phagocytes, mast cell recruitment, nor func-
tionally impaired epithelial barrier integrity in persistently infected 
adult animals (Fig. 2, A to D, and fig. S2A).
Nevertheless, persistent infection was associated with reduced 
body size (P < 0.001) and weight gain (P < 0.001) (Fig. 2, E to G, and 
fig. S2, B and C), and this phenotype lasted throughout adulthood 
(P < 0.05) (Fig. 2H). Although we noted moderately elevated intes-
tinal fluid and fecal humidity in infected animals (P < 0.05 and 
P < 0.01) (Fig. 2I), careful analysis of the propulsive bowel move-
ments (Fig. 2J), food intake (Fig. 2K), energy absorption (Fig. 2L), 
and body weight gain (P < 0.01) (Fig. 2M) clearly demonstrated that 
the reduced weight gain in G. lamblia–infected animals was not due 
to reduced food intake, diminished passage time, or impaired energy 
absorbance from ingested food. Thus, in addition to the enhanced 
susceptibility of malnourished adult animals to G. lamblia infection 
(21), infection of healthy neonate mice led to prolonged parasite 
persistence. Parasite persistence contributed to reduced weight gain 
and impaired linear growth that was not explained by the results 
from the analyses of mucosal barrier function (Fig. 2, C and D).
Identification of host factors driving G. lamblia persistence
Animals infected neonatally did not clear the parasite when they 
reached adulthood, although naive adult animals exposed to 
G. lamblia were resistant to infection. This suggested that the para-
site manipulated the host during the postnatal period to favor per-
sistence. However, the intestines of G. lamblia–infected adult 
animals revealed no apparent histopathological or immunological 
alteration, immune cell infiltration, or impaired barrier function 
(Figs. 1D and 2, A to D).
Careful investigation at autopsy revealed markedly fewer filled 
gall bladders in infected (30%) versus healthy age-matched control 
animals (80%; P < 0.05) (Fig. 3, A and B). Transcriptional and mass 
spectrometric analyses of liver tissue excluded reduced bile synthe-
sis in infected animals as an underlying cause (fig. S3, A and B). 
There were no identifiable changes in the hepatic expression of key 
enzymes, from both the classical and alternative bile synthesis 
pathways (fig. S3A). In addition, liver tissue showed no alteration 
in the concentration of major primary and secondary bile acid 
species (fig. S3B). Instead, we noted highly elevated mRNA ex-
pression of the bile secretion–promoting gut hormone cholecys-
tokinin in the intestinal epithelium of infected animals (P < 0.0001) 
(Fig. 3C). Enhanced bile secretion and enterohepatic circulation 
were confirmed by elevated blood concentrations of the major 
unconjugated bile acid components in mice: cholic acid (CA), 
–murocholic acid (MCA) and –murocholic acid (MCA; P < 0.01) 
(Fig. 3D).
Bile acids represent a major bile constituent and exert both 
growth-promoting and antiparasitic activity (27–31). Bile concen-
trations >1% inhibited parasite growth in vitro (Fig. 3E). The peak 
luminal bile concentrations in the adult host could have impeded 
infection. However, neither luminal bile acid scavenging via chole-
styramine administration in adult mice before and after G. lamblia 
infection nor repeated oral administration of high bile concentra-
tions in neonatally infected, persistently G. lamblia–positive mice 
altered the course of the infection (Fig. 3, F and G, and fig. S3C). 
Conversely, moderately enhanced bile acid concentrations promoted 
G. lamblia growth in vitro with maximal growth stimulation at 0.1% 
bile supplementation, consistent with the original report on the 
growth-promoting activity of mammalian bile on axenic growth of 
G. lamblia (Fig. 3E) (28, 31). Thus, enhanced bile secretion might 
contribute to parasite persistence. Both commercially available 
bovine bile, commonly used as medium supplement, and murine 
bile obtained by gall bladder puncture enhanced the in vitro growth 
rate of G. lamblia trophozoites (Fig. 3H). The taurine-conjugated 
bile acid species taurocholic acid (TCA), most abundantly found in 
liver and proximal intestinal tissue, exerted a particularly strong 
growth-promoting effect (Fig. 3I). However, comparative mass 
spectrometric analysis of conditioned medium after 24 hours of 
parasite culture with fresh growth medium revealed no detectable 
consumption of murine or bovine bile acids by G. lamblia (Fig. 3J 
and fig. S3D). This indicated that bile acids promoted G. lamblia 
growth but did not represent an energy source for the parasite 
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We next searched for other energy-rich constituents in bile that 
could represent possible metabolic substrates and might promote 
parasite growth. Decreased concentrations of the lysophosphatidyl-
cholines (LysoPC) 16:0, 18:0, and 18:2 were observed after in vitro 
culture of G. lamblia (P < 0.01) (Fig. 4, A to C, and fig. S4A). Sup-
plementing the growth medium with 
LysoPC(16:0), LysoPC(18:0), or a mix-
ture of LysoPC(16:0) and LysoPC(18:0) 
at 0.04 mM consistently enhanced 
G. lamblia proliferation (Fig. 4D). Sev-
eral additional in vivo findings supported 
that LysoPC promoted G. lamblia growth. 
First, the intestinal epithelial mRNA ex-
pression of intestinal phospholipase A2 
(PLA2), the enzyme responsible for 
transforming bile-derived phosphati-
dylcholine (PC) to LysoPC, was higher 
in G. lamblia–infected animals (P < 0.05) 
(Fig. 4E) (32). Second, the LysoPC con-
centration was lower in blood samples 
from infected animals than age-matched 
healthy controls (P < 0.01) (fig. S4B). 
Third, the susceptibility of adult mice to 
oral G. lamblia infection was enhanced 
by orally administered LysoPC alone 
(P < 0.05) and, even more so, in combi-
nation with bile, which together resulted 
in 100% G. lamblia–positive animals at 
4 weeks p.i. (P < 0.01) (Fig. 4F). In con-
trast, oral administration of the same 
dose of bile alone did not enhance the 
susceptibility to infection (Fig. 4F). 
Last, reduced LysoPC concentrations in 
bile fluid of multiple drug resistance 2 
(Mdr2) gene-deficient mice (33) led to 
spontaneous clearance in 40% of neo-
natally infected mice at the age of 7 weeks 
(Fig. 4G). Thus, G. lamblia may have 
induced bile fluid secretion, and bile- 
derived PC converted to LysoPC in 
combination with conjugated bile acids 
might have supported parasite growth.
Functional consequences 
of persistent G. lamblia infection
Persistently G. lamblia–infected animals 
had lower body weights and linear 
growth after weaning, consistent with 
associations seen in endemic areas 
(Fig. 2, F to H) (7, 10). Given that re-
duced linear growth and weight gain in 
developing countries have previously been 
associated with altered microbiomes, 
we next analyzed enteric microbiota com-
position (34). The small (P < 0.05) and 
large (P  <  0.01) intestinal microbiota 
composition differed between G. lamblia– 
infected adult animals and age-matched 
controls (Fig. 5A). This difference was 
observed in adult mice but not in neonates (fig. S5A). This result 
suggested that the G. lamblia–induced alteration of bile secretion or 
the mucosal adaptive immune system that matured after weaning 
may represent the underlying mechanism (35). In addition, the lu-




















































































































Fig. 1. Neonatal mice infected with G. lamblia show persistent infection. (A) Three-day-old (neonate) or 4-week-
old (adult) mice were orally infected with 2 × 105 (neonates) or 1 × 107 (adults) trophozoites of G. lamblia. The pres-
ence of G. lamblia antigen in fecal material was monitored weekly post-infection (p.i.) (n = 11 per group from two to 
three litters). (B) Three-day-old male and female mice were orally infected with G. lamblia trophozoites, and fecal 
G. lamblia antigen was monitored weekly (n = 9 to 10 per group from two litters). (C) Hematoxylin and eosin–stained 
representative tissue section of the mouse proximal small intestine. Tissue was obtained from mice that had been 
infected at 3 days of age, at 4 weeks p.i. [n = 4 from two litters; scale bar, 25 m; scale bar (inset), 5 m]. (D) Represen-
tative transmission electron microscopy images of mouse proximal small intestine. Tissue was obtained from mice 
that had been infected at 3 days of age, at 8 weeks p.i. [n = 4 from two litters; scale bar (left), 500 nm; scale bar (right), 
200 nm]. (E) Counts of viable trophozoites per gram intestinal tissue in mice infected with G. lamblia at 3 days of age, 
at 1, 4, and 10 weeks p.i., are shown. Proximal, middle, and distal small intestinal tissues were longitudinally opened 
and incubated on ice on a shaker for 2 hours at 150 rpm. Viable (motile) trophozoites were quantified microscopically 
in a hemocytometer (n = 4 to 5 per group from two litters). (F) Genome equivalents per gram intestinal tissue at 1, 4, 
and 10 weeks p.i. were quantified by quantitative PCR using the dilution series of a standard with a known number of 
viable trophozoites (n = 4 to 7 per group from two litters). Graphs show means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, 
and ****P < 0.0001 by Mantel-Cox test (A and B) or two-way ANOVA with Bonferroni post-test (E and F). All data are 
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observed changes in the gut microbiota composition (36). To eval-
uate the altered enteric microbiota’s possible role in infected animals’ 
reduced body weight gain, we next transferred large intestinal con-
tents of infected and age-matched control animals by oral gavage to 
germ-free C57BL/6J mice, using two different approaches. Trans-
ferring the enteric microbiota of adult mice during chronic infec-
tion or after spontaneous clearance of G. lamblia did not influence 
the body weight of germ-free recipients (fig. S5, B to E). Comparative 
analysis in donor and recipient animals confirmed the efficiency of 
the gut microbiota transfer and the establishment of a highly diverse 
gut microbiota in the recipient animals (fig. S5, F and G). Thus, the gut 
microbiota transfer experiments were unable to provide evidence for 
a direct functional effect of the altered microbiota composition on 
the reduced growth and weight gain in chronically infected animals.
Analyzing the observed gut microbiota changes after parasite in-






































































































































































































































CTL G.l. CTL G.l. CTL G.l. CTL G.l. CTL G.l.
10 min 30 min
Fig. 2. Parasite persistence leads to impaired 
growth and weight gain in mice.  (A  and 
B) Flow cytometric counts for (A) lamina propria 
macrophages, monocytes, and polymorphonu-
clear cells as well as (B) mast cells in the small 
intestine (SI) of mice infected at 3 days of age 
with G. lamblia (G.l.) at 4 weeks p.i. compared to 
age-matched control mice (CTL) (n = 11 per group 
from two litters). (C) Intestinal permeability at 
4 weeks p.i. is shown. Fluorescence was quanti-
fied in serum samples obtained 4 hours after 
administration of 4-kDa FITC-dextran by oral 
gavage of mice infected with 2 × 105 G. lamblia 
trophozoites at 3 days old compared to healthy 
age-matched control animals (n = 6 to 7 per 
group from two litters). (D) Serum endotoxin con-
centrations at 7 weeks p.i. of 3-day-old mice with 
2 × 105 G. lamblia (G.l.) trophozoites compared to 
healthy age-matched control animals. Endotoxin 
was quantified in 1:10 diluted serum samples using 
a limulus assay (n = 3 to 8 per group from two 
litters). (E and F) Body size (nose to tail) of mice 
infected at 3 days old with 2 × 105 G. lamblia tropho-
zoites (G.l.) at 4 weeks p.i. compared to healthy 
age-matched control animals (CTL) (n = 7 to 9 per 
group from two litters). (G and H) Total body 
weight at 4 weeks p.i. (G) and the time course 
of body weight between 4 and 20 weeks p.i. (H) 
for mice infected at 3 days old with G. lamblia 
compared to age-matched control animals (n = 7 to 
9, per group from two litters). (I) Water content in 
duodenum (Duo), jejunum (Jej), ileum (Ile), and 
colon (Col) tissues as well as in feces at 4 weeks 
p.i. for mice infected at 3 days old or age-matched 
control animals (n = 5 to 13 per group from two 
to three litters). (J) Intestinal transit of charcoal 
10 and 30 min after oral administration as per-
centage of total small intestine length is shown. 
Four-week-old mice infected with 2 × 105 G. lamblia 
trophozoites at the age of 3 to 4 days (G.l.) or 
healthy age-matched control animals (CTL) were 
analyzed (n = 7 to 9 per group from two litters). 
(K to M) Metabolic energy monitoring of G. lamblia– 
infected mice (G.l.) and age-matched control ani-
mals (CTL) for (K) total solid food intake per week 
(g) and (L) energy absorbed from food per week 
(kJ) as measured by calorimetric analysis of col-
lected feces; also shown is (M) the total body weight 
increase per week (g) (n = 5 to 7 per group from two 
litters). Graphs show means ± SD; *P < 0.05, **P < 0.01, 
and ***P < 0.001 by two-way ANOVA with Bonferroni 
post-test (A and H to J) or Mann-Whitney test (B to 
D, F, G, and K to M). All data are representative of 
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intestine (P  <  0.05) (Fig.  5B). Although Staphylococcus was less 
abundant in infected adult animals (P < 0.01), it increased for the 
family Coriobacteriaceae (P < 0.01) and the genus Enterorhabdus 
(P < 0.01) therein (Fig. 5, C to E). Coriobacteriaceae very efficiently 
deconjugate bile acids (37). Mass spectrometric bile acid analysis 
revealed a reduction in all major taurine-conjugated bile acids includ-
ing TCA (P < 0.05), -tauromuricholic acid (TMCA; P < 0.01) and 
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Fig. 3. Enhanced bile secretion 
during G. lamblia persistence. 
(A) Macroscopic view of the abdom-
inal situs of 4-week-old persistently 
G. lamblia–infected mice (G.l.; right) 
and healthy control animals (CTL; left). 
(B) Number of animals with full or 
empty gall bladders among persistently 
G. lamblia–infected mice (G. lamblia) 
or healthy age-matched control ani-
mals (CTL) was examined with food 
ad libitum (normal), after fasting for 
12 hours (Fasting 12 hours) or 30 min 
after a 12-hour fasting period (+ Food 
30 min) (n = 5 to 23 per group from 
two to four litters). (C) Quantitative 
RT-PCR for cholecystokinin mRNA 
expression in intestinal epithelial cells 
isolated from the small intestine of 
persistently G. lamblia–infected mice 
(G.l.) or healthy age-matched control 
animals (CTL) after fasting for 12 hours 
(Fasting 12 hours) or 30 min after a 
12-hour fasting period (Food 30 min) 
is shown. Values were normalized to 
the expression of the housekeeping 
gene hprt (n = 6 to 11 per group from 
two to three litters). (D) Quantitative 
analysis of the concentration of cho-
lic acid (CA) and -murocholic acid 
and -murocholic acid (MCA) in pe-
ripheral blood from nonfasted mice 
4 weeks p.i. or age-matched nonfasted 
control animals (n = 10 per group from 
two litters) is shown. (E) G. lamblia 
trophozoite count after G. lamblia 
incubation in vitro in culture medium 
supplemented with the indicated 
concentrations (vol %) of total bovine 
bile. The means of two independent 
technical replicates are shown. (F) Per-
centage of fecal G. lamblia antigen–
positive animals after oral infection 
of adult mice at the age of 4 weeks 
with 1 × 107 G. lamblia trophozoites 
after pretreatment for 1 week with 
cholestyramine (daily oral gavage of 
500 mg/kg body weight from 1 week 
before infection until the end of the 
experiment) or PBS (n = 7 per group from 
two litters). (G) Three-day-old neonatal 
mice were infected with G. lamblia and 
treated by oral administration of total bovine bile (daily oral gavage of 70 mg/kg of body weight) or PBS from 4 weeks p.i. until the end of the experiment. Shown is the 
percentage of fecal G. lamblia antigen–positive animals over the course of the experiment (n = 6 to 7 per group from two litters). (H) Growth rate of G. lamblia in culture 
medium supplemented with 0.1% total bovine bile or 0.1% total murine bile after 48 hours (n = 4 per group). (I) Growth rate of G. lamblia in culture medium supplemented 
with taurocholic acid (TCA) or CA after 48 hours (n = 4 per group). (J) Comparative mass spectrometric analysis of bile acids in culture medium supplemented with bovine 
bile before (blue; CTL) and after (orange; G. lamblia) in vitro culture of G. lamblia for 48 hours (one of three independent experiments is presented). Graphs show 
means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by chi-square test (B), Mann-Whitney test (C, D, and H), Mantel-Cox test (F and G), or two-way ANOVA with 
Bonferroni post-test (I). All data are representative of two to three independent in vivo experiments. TCA, taurocholic acid; GCA, glycocholic acid; TDCA, taurodeoxycholic acid; 
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acid (TUDCA; P < 0.05) in the small intestinal tissue of G. lamblia–
infected mice (Fig. 5F). Conversely, the corresponding unconjugated 
bile acids MCA (P < 0.01) and MCA (P < 0.01) and chenodeoxy-
cholic acid (CDCA; P < 0.05) were higher in the intestinal lumen 
and serum of infected adult animals (Figs. 5F and 3D). G. lamblia 
exerted no bile salt hydrolase activity, 
and free taurine did not support G. lamblia 
growth in vitro (fig. S5H). Thus, en-
hanced bile salt deconjugation most likely 
had no direct nutritional benefit for the 
parasite (30).
Instead, enhanced bile acid deconju-
gation in combination with the ob-
served elevated enterohepatic cycle may 
have affected mouse host metabolism. CA 
and CDCA are farnesoid X receptor (FXR) 
agonists, whereas taurine-conjugated 
murocholic acids, the dominant bile 
acid type in the murine intestine, are 
potent FXR antagonists (38). The 
observed increase in CDCA in combi-
nation with a reduction in intestinal 
taurine-conjugated murocholic acids in 
G. lamblia–infected mice might, there-
fore, enhance FXR activation and, in 
turn, increase the expression of fibro-
blast growth factor 15 (FGF15). Intesti-
nal epithelial FGF15 expression was 
higher in infected animals (P  <  0.05) 
(Fig. 6A). FGF15 stimulates the FGF re-
ceptor 1 (FGFR1) in peripheral tissues 
and helps regulate metabolism, promote 
lipid oxidation and energy expenditure 
in adipocytes, and reduce body adipose 
tissue (39). Consistent with these func-
tions, our metabolomic analysis revealed 
moderately increased concentrations of 
acylcarnitines in the serum of infected 
animals (Fig. 6B; fig. S6, A to C; and ta-
ble S1). Acylcarnitines have also been 
found in the urine of G. lamblia–infected 
mice (20). Enhanced acylcarnitines have 
also been observed in healthy humans 
after fasting or exercise as a sign of 
excess lipolysis and mitochondrial over-
load (40, 41) and in children with envi-
ronmental enteric dysfunction and 
increased intestinal permeability (42). 
Moreover, whole-body imaging and tis-
sue dissection revealed decreased total 
adipose tissue (P < 0.05) (Fig. 6C and 
fig. S6, D and E), perigonadal adipose 
tissue (P < 0.01) (fig. S6, F and G), sub-
cutaneous adipose tissue (P  <  0.05) 
(Fig. 6, D to F), and brown adipose tis-
sue (P  <  0.05) (Fig.  6G and fig. S6, H 
and I) in G. lamblia–infected mice ver-
sus healthy control animals. G. lamblia–
infected animals also exhibited lower 
serum cholesterol concentrations (P < 0.05) (fig. S6J). Thus, sec-
ondary to altered gut microbiota composition and bacteria-induced 
bile salt deconjugation, metabolic dysregulation might cause the 
reduced weight gain and linear growth in persistently G. lamblia–







































































































































































Fig. 4. Bile-derived LysoPC may be a metabolic substrate for G. lamblia. (A) Comparative mass spectrometric 
analysis of the peak areas of LysoPC in culture medium supplemented with bovine bile before (blue; CTL) and after 
(orange; G. lamblia) in vitro culture of G. lamblia for 48 hours (one of three independent experiments is shown). (B and 
C) Quantitative analysis of LysoPC(16:0) (B) and LysoPC(18:0) (C) concentrations in culture medium (mg/liter) without 
bile (no bile) or supplemented with 0.1% bovine or murine bile before and after in vitro culture of G. lamblia for 
48 hours (n = 3 per group). (D) The effect of LysoPC(16:0) (20 mg/liter), LysoPC(18:0) (20 mg/liter), or a mixture of 
LysoPC(16:0) and LysoPC(18:0) (20 mg/liter) in culture medium on G. lamblia growth after 48 hours of culture (n = 4 
per group). (E) Quantitative RT-PCR for PLA2 mRNA expression in intestinal epithelial cells isolated from persistently 
G. lamblia–infected mice 4 weeks p.i. or healthy age-matched control animals after fasting for 12 hours. Three-day-old 
mice were infected with 2 × 105 G. lamblia trophozoites. Values were normalized to the expression of the housekeep-
ing gene hprt (n = 5 to 6 per group from two litters). (F) Percentage of fecal G. lamblia antigen–positive mice after oral 
infection at 4 weeks with 1 × 107 G. lamblia trophozoites after 1 week of treatment with LysoPC with or without bovine 
bile or water (CTL). Treatment was LysoPC (100 g/liter) with or without total bovine bile (100 g/liter) in the drinking 
water, provided ad libitum from 1 week before infection until treatment end (n = 7 per group from two litters). 
(G) Percentage of fecal G. lamblia antigen–negative animals 4 weeks after weaning after oral infection of 3-day-old 
FVB Mdr2+/+ mice or FVB Mdr2−/− mice (n = 11 to 15 per group from three litters). Graphs show means ± SD measured 
by two-way ANOVA with Bonferroni post-test (B and C), Mann-Whitney test (E), or Mantel-Cox test (F); *P < 0.05, 
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PCs consumed by G. lamblia, as illustrated by elevated hepatic con-
centrations of glycerophospholipids and PCs, might have further 
aggravated the observed metabolic phenotype (fig. S6C and table 
S2). Starvation clearly showed the severity of the G. lamblia– 
induced global metabolic alteration in mouse hosts. After 16 hours 
of food deprivation, G. lamblia–infected animals were unable to 
maintain body temperature (P < 0.05) (Fig. 6H) and fell in a turgor- 
like state of reduced mobility (movies S1 and S2). This phenotype 
was fully reversible after administration of solid food (Fig. 6H). 
Thus, despite the restricted anatomical localization in the intestinal 
lumen, G. lamblia severely altered the mouse host’s lipid metabo-
lism, leading to reduced body weight gain and linear growth. Quan-
tifying the human homolog FGF19 in serum samples obtained from 
children in an endemic area in Africa (43) revealed higher FGF19 
concentrations in G. lamblia–positive children compared to G. lamblia–
negative controls (P < 0.05) (Fig. 6I).
DISCUSSION
In some areas of the world, G. lamblia is highly endemic, with a 
prevalence among children reaching well above 30% (8, 10). Detec-
tion of this protozoan in this population is not linked to acute diar-
rheal disease (5–8) but has been associated with failure to thrive 
(44, 45), reduced weight-for-age (12, 46, 47), lower height-for-age 
(linear growth) (12, 17, 46, 48, 49), and cognitive impairment (50). 
The neonatal murine infection model used here mimics the de-
scribed associations in humans. Infection of neonatal mice led to 
chronic parasite carriage without the symptoms typically associated 
with acute G. lamblia infection. In addition, it has been reported 
that mouse neonatal infection did not alter either the anatomical 
crypt-villus architecture or enterocyte ultrastructure, induce infil-
tration by immune cells, impair epithelial barrier integrity, or re-
duce nutrient absorption (51). This is different from an adult mouse 
infection model, where T lymphocyte–induced epithelial damage 
was observed (52). Accordingly, this neonatal mouse model may 
help reveal why early exposure in humans predisposes to chronic 
carriage and secondary metabolic consequences leading to reduced 
body weight, growth deficits, and cognitive impairment (7, 10).
Infection of neonatal mice with G. lamblia trophozoites has pre-
viously been reported (23, 24). Although these studies noted initial 
parasite growth, they observed spontaneous clearance of the para-
site 3 to 4 weeks after infection in contrast to the more than 20 weeks 
of parasite persistence in our study. The reason for the different 
outcome is not entirely clear; the use of different parasite strains 
(Portland 1, BRIS/83/HEPU/106 or BRIS/95/HEPU/2041 versus 
strain GS, clone H7 in our study), mouse strains and differences in 
their mucosal immune systems (CF-1 and Quackenbush Swiss mice 
versus C57BL/6 mice in our study), and environmental conditions 
in the animal facility might have contributed (23, 24, 35). Chronic 
infection was observed in numerous experiments performed in two 
independent animal facilities over a period of 8 years.
Our results confirm that bile is a critical growth factor for 
G. lamblia in vivo (28). Given that G. lamblia has limited ability to 
synthesize lipids, bile might be a lipid source for membrane and 
organelle biosynthesis, energy production, and growth (53, 54). 
That G. lamblia can stimulate bile secretion accords with previous 
reports that observed increased spontaneous smooth muscle con-
tractions in G. lamblia–infected mice and enhanced urinary excretion 









































































































































































Fig. 5. Infection-induced changes in the enteric microbiota and bile salt hydro-
lase activity. (A) Principal coordinate analysis of the small intestinal (top) and co-
lonic (bottom) microbiota composition of 4-week-old mice infected with G. lamblia 
as 3-day-old neonates compared to age-matched healthy control animals, as de-
termined by 16S ribosomal RNA gene amplicon sequencing (n = 4 to 5 per group 
from two litters). d, (dis)similarity distance of the generalized UniFrac defined by 
the distance between two grid lines. (B) Richness expressed as the number of 
operational taxonomic units (OTUs) detected in the small intestinal microbiota of 
4-week-old persistently G. lamblia–infected (G.l.) mice or age-matched control ani-
mals (n = 4 to 5 per group from two litters). (C to E) Relative abundance of signifi-
cantly different OTUs (phyla, families, and genera) in the colonic microbiota of 
4-week-old persistently G. lamblia–infected mice (G.l.; n = 5 from two litters) or age-
matched control animals (n = 4 to 5 per group from two litters). (F) Global mass 
spectrometric bile acid composition analysis of the small intestinal contents of 
adult mice chronically infected with G. lamblia or healthy control animals (CTL) is 
shown (n = 7 to 8 per group from two litters). Graphs show means ± SD; *P < 0.05 
and **P < 0.01, by PERMANOVA (A) and Mann-Whitney test (B to F) (73). All data are 
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abolishes bile’s trough and peak concentrations in the small intes-
tine during fasting and after food intake, respectively, leading to 
more continuous bile constituent release into the proximal small 
intestine. Unexpectedly, we identified LysoPC as a growth factor for 
G. lamblia in vivo. Relatedly, PC is a predominant phospholipid 
class (61.4%) in G. lamblia (53, 56) and urinary concentrations of 
choline breakdown metabolites in mice were higher after infection 
(20). G. lamblia can also internalize PC and LysoPC and convert 
them into various downstream lipids such as phosphatidylserine, 
phosphatidylethanolamine, and phosphatidylglycerol (28, 54). PC 
is a major constituent of bile and is rapidly converted into LysoPC 
by the small intestinal PLA2. G. lamblia infection raised epithelial 
expression of the host PLA2 in a study using IL-17ra−/− mice, and 
this was shown to depend on interleukin-17 (IL-17) secretion (32). 
In addition, G. lamblia itself expresses two phospholipases that con-
vert PC to LysoPC (57). PC also represents a major constituent of 
breast milk and might contribute to persistent infection upon chal-
lenge of neonatal animals (58). Besides LysoPC, bile acids pro-
moted G. lamblia growth, although no bile acid consumption was 
detected. Because in humans, bile acids have been shown to be 
internalized by the parasite and thus might support the intake of 
lipids such as LysoPC (27, 28, 30). Consistently, bile acids were 
shown to enhance the intake of lecithin, and oral bile acid (glyco-
cholic acid) administration was shown to promote the luminal 
growth of the related parasite Giardia muris (28, 59). Moreover, 
bile salts protect the protozoan parasite from fatty acid–mediated 
killing in the small intestine (60). Increased bile secretion might 
thus serve both to provide lipid substrates for lipid remodeling 
and energy metabolism and to support parasitic lipid intake. In 
addition, elevated bile secretion may help protect G. lamblia–positive 






















































































































































































Fig. 6. Metabolic consequences of 
persistent G. lamblia infection. 
(A) Quantitative RT-PCR for Fgf15 
mRNA expression in the small intes-
tine epithelial cells of persistently 
G. lamblia–infected mice (G.l.) com-
pared to healthy age-matched con-
trol animals (CTL) after fasting for 
12 hours (Fasting) or after fasting for 
12 hours and access to food for 30 min 
(Food +30 min). Values were normal-
ized to the expression of the house-
keeping gene hprt (n = 5 to 10 per 
group from two to three litters). 
(B) Volcano plot of lipophilic metab-
olites, as measured by mass spec-
trometry, in serum of mice persistently 
infected with G. lamblia versus healthy 
age-matched control animals (CTL) 
(n = 10 to 11 per group from two to 
three litters). Black diamond, sugars; 
purple diamond, custom metabolo-
mics indicator. The log2 fold change 
[Log(2)fc] between G. lamblia–infected 
mice and healthy control animals is 
shown. (C to G) Quantitative imaging 
of visceral and subcutaneous adipose 
tissue of control (CTL) and G. lamblia– 
infected (G.l.) mice at 4 weeks p.i. is 
presented. (D) Three-dimensional (3D) 
volume renderings of segmented 
visceral (green) and subcutaneous 
(blue) adipose tissue and lung (pink) 
after CT imaging (top) and 2D cross- 
sectional CT images in transversal 
planes of the abdomen (bottom). (C to 
G) Quantitative comparative analy-
sis of (C) total adipose tissue, (D and 
E) subcutaneous adipose tissue, (D 
and F) visceral adipose tissue, and 
(G) total brown adipose tissue (BAT) in relation to total body volume (%) was performed (n = 4 to 5 per group from two litters). (H) Body temperature as determined 
by contactless infrared temperature measurement of G. lamblia–infected mice and healthy age-matched control animals (CTL) 1 day before starvation, after 16 hours 
of starvation, and 1 day later after free access to food (n = 5 to 7 per group from two litters). (I) Serum FGF19 concentrations determined by PCR in serum samples 
from children who were positive or negative for G. lamblia infection as part of an African cohort study on diarrheal diseases (n = 23 to 60 per group). Graphs show 
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Alterations in the overall microbiota composition occur in the 
small and large intestines of adult G. lamblia–positive animals 
(20, 36). Because these changes are greater in adults than in acutely 
infected neonatal animals, enhanced bile acid secretion might ex-
plain the observed alteration of the gut microbiota. The higher 
abundance of bacteria from the genus Enterorhabdus, which are 
known to deconjugate bile salts, explains the observed increase in 
deconjugated and hydroxylated bile acids such as CDCA. The ele-
vated bile acid deconjugation is also consistent with previously 
reported higher taurine concentrations in urine samples from 
G. lamblia–infected animals (20). Although changes in the gut 
microbiota composition have been associated with malnutrition 
and growth retardation (34), our gut microbiota transfer experi-
ments to germ-free animals failed to provide evidence that the 
G. lamblia infection–induced alterations of the gut microbiota per 
se were sufficient to cause reduced body weight gain. However, one 
should keep in mind that inefficient transfer of specific fastidious or 
extremely sensitive taxa or neonatal age-restricted effects of the gut 
microbiota may limit the informative value of this experimental 
approach. Thus, the parasite-induced increased bile secretion and 
accelerated enterohepatic cycle in combination with gut micro-
biota alterations with elevated bile salt hydrolase activity might lead 
to reduced weight gain. The increased concentrations of unconju-
gated bile acids might additionally explain the moderately elevated 
intestinal fluid and fecal humidity in infected adult animals, con-
sistent with previous reports on the bile acids’ effect on fluid secre-
tion (61).
The parasite-induced alteration of the host’s bile physiology 
explains the observed metabolic phenotype in our study (fig. S8). By 
consuming LysoPC, G. lamblia withdraws energy-rich substrates 
from the host’s metabolism. Accordingly, infected animals had in-
creased PC concentrations in liver tissue, most probably because of 
the organism’s attempt to refill the biliary PC pool. Enhanced con-
centrations of the FXR agonist CDCA and lower concentrations of 
the FXR antagonist TMCA enhanced FXR stimulation and epithe-
lial FGF15 expression, thereby raising energy expenditure and 
diminishing adipose tissue in infected animals (38, 39, 62). In addi-
tion to its role as a hepatic feedback signal for bile acid synthesis and 
release, FGF15 stimulates the FGFR1  in peripheral adipose tissue 
(63). FGF15 overexpression has been shown to increase energy 
expenditure and decrease adiposity in vivo (39, 64). Consistent with 
these observations, elevated FGF15 in infected animals was associ-
ated with globally reduced adipose body tissue. Further studies, 
however, are needed to establish a causative role of FGF15 for the 
observed reduction in the adipose tissue mass. The loss of adipose 
tissue rendered the animals unable to maintain energy homeostasis 
during starvation, as illustrated by reduced mobility and lowered 
body temperature under food restriction. Infection-induced energy 
utilization inefficiency aligns with a recent study that showed 
G. lamblia–infected animals experiencing protein deficiency had 
elevated -oxidation metabolites in urine and reduced body weight 
(20). With elevated serum acylcarnitines and signs of increased fatty 
acid ß-oxidation, the metabolic profile in G. lamblia–infected ani-
mals also reveals similarities with the metabolism of children with 
environmental enteric dysfunction, a widespread condition of chil-
dren in developing countries and an accepted causative factor for 
impaired linear growth (42). A similar mechanism might thus be 
responsible for reduced body weight gain and linear growth reported 
in G. lamblia–infected human infants in endemic areas. G. lamblia–
positive children had higher concentrations of the human FGF15 
homolog, FGF19.
Although our study identified mechanisms in our animal model 
that may have contributed to reduced growth and body weight gain 
in children in endemic areas, much work remains to be done. For 
example, the mechanisms that render neonate mice susceptible to 
chronic parasite carriage and the role of the developing mucosal 
innate and adaptive immune system remain largely unresolved. In 
addition, how G. lamblia induces epithelial cholecystokinin secre-
tion, which factors alter the enteric microbiota composition, and 
whether and to what extent enhanced FGF15/FGFR1 signaling con-
tributes to the observed metabolic dysregulation and reduced 
growth require further work. Moreover, future prospective longitu-
dinal studies are needed to analyze disease-associated changes such 
as altered bile acid and lipid metabolism as well as enteric micro-
biota composition in human infants in endemic areas and to confirm 
the G. lamblia infection–induced elevation of FGF19 as a causative 
factor for reduced body weight gain and linear growth. These stud-
ies should include additional cofactors such as nutritional status, 
dietary factors, and infections with other enteropathogens.
Together, our data suggest that neonatal G. lamblia infection of 
mice may mirror clinical features of infant G. lamblia infection in 
endemic areas, namely, delayed growth and curtailed body weight 
gain in the absence of intestinal inflammation and diarrhea. Our 
results illustrate the details of host-parasite interactions in a neonatal 
mouse model of infant G. lamblia infection and provide a plausible 
mechanistic explanation for altered lipid metabolism and growth 
retardation in persistently infected children.
MATERIALS AND METHODS
Study design
The primary objective of this study was to use infection of neonatal 
mice with the protozoan parasite G. lamblia to characterize age- 
dependent consequences of G. lamblia infection and to identify po-
tential underlying mechanisms. Using in vitro culture assays and 
in vivo infection, we analyzed how persistent luminal G. lamblia 
infection dysregulated the host’s bile acid homeostasis, enteric 
microbiota, and lipid metabolism, leading to impaired growth and 
reduced weight gain. All mouse litters (7 ± 2 pups per litter) or adult 
mice used in our experiments were randomized for treatment and 
optimized for sample size and sex matching. Except for the analysis 
of human sera and the whole-body imaging of mice, all experiments 
were repeated at least twice and results were pooled for analysis. All 
experiments were performed on at least two litters. For each exper-
iment, the numbers of mice and experimental replicates are indicated 
in the figure legends. Samples were not excluded from analysis, and 
outliers are visible on the graphs. Investigators were not blinded 
during the experiments.
All animal experiments were performed in compliance with the 
German animal protection law (TierSchG) and approved by the 
local animal welfare committees, namely, the Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit 
Oldenburg, Germany (33.12.42502-04-14/1344) and the Landesamt 
für Natur, Umwelt und Verbraucherschutz, North Rhine Westfalia 
(84-02.04.2015.A063 and 84-02.04.2016.A207). C57BL/6J wild-type 
(WT), FVB WT, and FVB Mdr2−/− mice were bred locally and held 
under specific pathogen–free or germ-free conditions at the Insti-
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Hospital. Germ-free animals were provided by the animal facility at 
Hannover Medical School. The day of birth was considered day 1, 
i.e., animals infected at day 3 were about 48 hours old and verified 
to have ingested breast milk (milk spot). The human serum samples 
were derived from a previously published pediatric hospital–based 
cohort study on the epidemiology of malaria coinfections in Ghanaian 
children (43). This study was approved by the Ärztekammer 
Hamburg (no. PV4592) and the Committee on Human Research, 
Publications and Ethics, School of Medical Science, Kwame Nkrumah 
University of Science and Technology, Kumasi, Ghana (no. CHRPE/
AP/427/13).
In vitro G. lamblia culture
G. lamblia ATCC 5058 (assemblage B, strain GS, clone H7) was used 
for all experiments in this study. Assemblage B strains account for the 
majority of human cases. G. lamblia medium was prepared by adding 
trypticase peptone (20 g; BD, no. 211921), yeast extract (10 g; Merck, 
no. WM983953), D(+) glucose (10 g; Sigma-Aldrich, no. G7528), NaCl 
(2 g; Sigma-Aldrich, no. S5886), K2HPO4 (1 g; Sigma-Aldrich, no. 
P2222), KH2PO4 (0.6 g; Sigma-Aldrich, no. P5655), l-cysteine (2 g; Serva, 
no. 17769), L(+) ascorbic acid (0.2 g; Sigma-Aldrich, no. 33034), am-
monium citrate (22.8 mg; Roth, no. CN77.1), bovine total bile (0.5 g; 
Sigma-Aldrich, no. B8381), ampicillin (50 g/ml; Roth, no. K029.2), 
and kanamycin (100 g/ml; Roth, no. T832.1) to 900 ml of distilled 
water and 100 ml of heat- inactivated bovine serum (PAN-Biotech). 
The pH was adjusted to 7.0 to 7.1, and the medium was sterile filtered 
using a 0.22-m vacuum filter (Pall). Culture flasks were kept at 
37°C under anaerobic conditions using an anaerobic atmosphere 
generation bag and airtight container (BioMérieux). G. lamblia was 
split upon confluency (i.e., every 2 to 3 days) at 1:10. To allow detach-
ment and harvest trophozoites for further use, culture medium was 
replaced with 5 ml of cold sterile Dulbecco’s phosphate-buffered 
saline (PBS) solution without Ca2+ and Mg2+ (Merck Millipore Bio-
chrom) and incubated on ice for 10 min. The trophozoite number 
was determined in a counting chamber by microscopy, and the sus-
pension was adjusted by centrifugation at 2000 rpm for 10 min at 4°C 
and resuspension to 107 or 108 trophozoites/ml for the infection of 
neonates or adult mice, respectively.
In vitro G. lamblia experiments
For in vitro growth experiments, G. lamblia trophozoites were seeded at 
a density of 105 trophozoites per well in 12-well plates. The number of 
viable parasites was determined after 48 hours of culture at 37°C under 
anaerobic conditions by detachment and counting as described above. 
The culture medium was supplemented with bovine bile at a concen-
tration of 0 to 5% (Sigma-Aldrich, no. B8381), mouse bile at a concen-
tration of 0.1% (collected by gall bladder puncture of healthy adult 
C57BL/6 mice), TCA at a concentration of 0 to 2.5 mM (Sigma-Aldrich, 
no. T4009), CA (Sigma-Aldrich, no. C1129), taurine (Sigma-Aldrich, 
no. T0625), or LysoPC C16:0 and/or C18:0 (Avanti, nos. 17364168 
and 19420576) at a concentration of 10 or 20 mg/liter.
In vivo G. lamblia infection experiments
All animals were derived from the same in-house breeding and bred 
in the same room and under the same conditions (hygiene, food, 
water, and bedding). Control and infection experiments were per-
formed in parallel, and litters were randomly assigned to the different 
experimental groups. Three-, 14-, 21-day-old neonate and infant 
C57BL/6J mice were infected with 2 × 105 G. lamblia trophozoites 
in 20 l of PBS by gastric gavage. Adult (4 to 8 weeks old) conven-
tionally raised C57BL/6, FVB WT, or FVB Mdr2−/− mice were 
infected with 1 × 107 G. lamblia trophozoites in 100 l of PBS by 
gastric gavage. Control animals were gavaged by PBS only (sham 
gavage). FVB WT and FVB Mdr2−/− mice were bred in the same 
room, but littermates from heterozygous breeding were not used, 
and the enteric microbiota was not determined. Body weight and 
food/water intake were monitored, and fresh fecal samples were 
collected weekly to detect G. lamblia antigen by enzyme-linked 
immunosorbent assay (ELISA) (IBL International). Intestinal and 
liver tissue and serum/plasma were obtained for quantitative PCR, 
histology, electron microscopy, primary intestinal epithelial cell 
isolation, flow cytometry, and determining metabolites and viable 
counts at the indicated time points after infection. To determine 
viable organ counts, animals were starved for 4 hours, at which 
point the intestine was cut into six parts, longitudinally opened, and 
incubated in cold PBS for 2 to 3 hours on ice. The tissue was repeat-
edly rinsed, and the viable trophozoite number was determined in a 
counting chamber by microscopy. Epithelial barrier integrity was 
determined by oral gavage–administered fluorescein isothiocyanate 
(FITC)–dextran (4 kDa; TdB Consultancy) at a concentration of 
750 mg/kg body weight. After 4 hours, the FITC-dextran concen-
tration in plasma was assessed using a SpectraMax i3 at an exci-
tation of 492 nm and an emission of 518 nm in combination with a 
serially diluted FITC-dextran standard. Results were expressed as 
g/ml of plasma. To measure tissue/fecal water content, duodenum, 
jejunum, and ileum, colon and feces from G. lamblia–infected and 
age-matched control animals were collected. Luminal content of 
the intestinal tissue or feces was weighed before and after the mate-
rial was dried at 55°C for 48  hours. The weight difference corre-
sponded to the water content in the gut lumen or feces and was 
expressed as percent of the total organ/fecal weight. To determine 
intestinal transit time, ground charcoal pieces (Sigma-Aldrich) 
were orally administered by gavage in 100 l (5% charcoal and 10% 
gum Arabica in PBS), and the distance that the charcoal had migrat-
ed through the small intestine was measured after 10 or 30 min. For 
cholestyramine treatment, 8-week-old mice remained untreated or 
received cholestyramine (500 g/g of body weight per day) by oral 
gavage. After 2 weeks of treatment, mice were infected with 107 G. 
lamblia trophozoites in 100 l of PBS by oral gavage. Body weight 
was monitored, and weekly fresh fecal samples were tested by ELI-
SA for the presence of G. lamblia antigen. For oral bile administra-
tion, adult 6-week-old persistently G. lamblia–positive animals in-
fected at the age of 3 days with 2  ×  105 trophozoites were left 
untreated or treated daily by oral gavage with total bile (70 g/g of 
body weight). Body weight was monitored, and fresh fecal samples 
were collected weekly to be tested by ELISA for the presence of G. 
lamblia antigen. For oral LysoPC treatment, 26-day-old mice were 
left untreated, treated daily with LysoPC [(16:0)/(18:0) at 1:1 ratio], 
treated daily with bile only, or treated daily with bile and LysoPC 
[(16:0)/(18:0) at 1:1 ratio] in drinking water [LysoPC(16:0) and 
(18:0) each at 1 g/liter, bovine bile if added at 1 g/liter]. At the age of 
28 days (i.e., 2 days after the first LysoPC treatment), the animals 
were infected with 107 G. lamblia trophozoites in 100 l of PBS by 
oral gavage. Body weight and food/water consumption were mon-
itored, and fresh weekly fecal samples were tested by ELISA for the 
presence of G. lamblia antigen. Two different approaches were ap-
plied to evaluate the altered enteric microbiota’s role in decreased 
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content obtained from either 4-week-old mice infected at the age of 
3 days or healthy age-matched animals was transferred to 8-week-
old germ-free mice. Second, large intestinal content obtained 
from mice that were infected as 3-day-old neonates and had 
spontaneously cleared the infection after >25 weeks and age-
matched healthy animals was transferred to 8-week-old germ-free 
mice. For both approaches, body weight and food/water consump-
tion were monitored and fresh fecal samples were collected weekly 
and tested by ELISA for the presence of G. lamblia antigen. There-
by, the only transient (first week after transfer) presence of G. lam-
blia in recipient animals after transfer of microbiota from G. lam-
blia–infected animals (approach 1) and the absence of G. lamblia 
antigen in recipient animals after transfer of microbiota from 
cleared animals (approach 2) were confirmed. These results are 
consistent with our observation that adult germ-free mice similar to 
adult conventional mice clear G. lamblia about 1 to 2 weeks after 
exposure (fig. S7). Parasite clearance might be specific for our 
model because other studies reported an elevated susceptibility of 
germ-free animals to G. lamblia infection (65, 66). To analyze G. 
lamblia–infected mice under starvation conditions, 4-week-old 
mice infected at the age of 3 days or healthy aged-matched control 
mice were starved for 12 hours (drinking water ad libitum). Half of 
the animals were sacrificed to obtain organs; the others were given 
food ad libitum for 30 min before sacrifice. Perigonal and brown 
adipose tissue were collected and weighed after cervical dislocation.
Analyzing human serum samples
Serum samples from 23 G. lamblia–positive and 60 G. lamblia–negative 
children, as determined by PCR from fecal samples, were obtained 
from the previously published study cohort (43), stored at −80°, and 
analyzed by ELISA for FGF19 concentration (DF1900, R&D Systems).
Lipid analysis in culture medium, liver, and intestinal tissue
To analyze lipid metabolites in culture medium, medium superna-
tants were centrifuged at 21,000g for 5 min at 4°C to remove parti-
cles and debris. Fifty microliters were used for separating bile acids 
and matching. To quantify LysoPC quantification, centrifuged 
supernatants were diluted 1:2002 in cold methanol to fit peak areas 
into established calibration curves. Liver and small intestine con-
tent (about 10 mg) were weighed into sterile ceramic bead tubes 
(NucleoSpin Bead Tubes, Macherey-Nagel) and extracted with 1 ml 
of chilled methanol, containing 0.2 ppm (parts per million) of 
deuterium-labeled bile acid mix (d5-TCA, d4-glycodeoxycholic 
acid, d4-CA, and d4-deoxycholic acid; table S3) as internal stan-
dards. Homogenizing and extracting samples were performed with 
Precellys Evolution homogenizer (Bertin Corp.; 4500 rpm; 40 × 3 s; 
pause time, 2 s). Samples were centrifuged at 21,000g for 10 min at 
4°C. Supernatants were transferred into sterile microcentrifuge tubes 
and stored at −80°C before analysis. LC-MS (liquid chromatography– 
mass spectrometry)–grade methanol, acetonitrile, isopropanol, and 
ammonium acetate were obtained from Fluka (LC-MS CHROMA-
SOLV). Glacial acetic acid was purchased from Biosolve (ULC/MS). 
Ultrapure water (milliQH2O) was derived from a Milli-Q apparatus 
(Milli-Q Integral Water Purification System). 1-Palmitoyl-sn-glycero-3- 
phosphocholine [LysoPC(16:0)] and 1-stearoyl-sn-glycero-3- 
phosphocholine [LysoPC(18:0)] were purchased from Sigma-Aldrich. 
Both were dissolved in pure methanol to a stock solution of 1 mg/ml 
(1000 ppm). LysoPCs were mixed, and an equidistant five-point 
calibration curve of 0.001 to 0.005 ppm was prepared to quantify 
LysoPCs in supernatants. To analyze bile acid, 34 and 4 deuterium- 
labeled bile acids (table S3) were used for identification and normal-
ization, respectively. Stock bile acid solutions were prepared (1 mg/ml) 
in pure methanol and stored in 4°C until analyses. A mixture com-
bining all bile acids (0.2 ppm) was analyzed simultaneously. Analy-
ses of bile acids, LysoPCs, and extracted samples were performed 
with ultrahigh-performance liquid chromatography (ACQUITY 
UPLC, Waters) coupled to MS, as described previously (67). More-
over, bile acids were measured in negative and LysoPCs in positive 
electrospray ionization mode. Bile acids were acquired in full-scan 
mode (50 to 1000 m/z), whereas LysoPCs were acquired in multiple 
reaction–monitoring mode with a 5-Da isolation window and 0.75-V 
fragmentation amplitude. Isolation masses of parent ions, major 
fragments, and retention times were as follows: LysoPC(16:0): 
[M  +  H]+: 464.60->478.4/14 to 15  min and [M  +  H]+: 524.40-
>506.4/15 to 16 min. For data processing, targeted peak picking of 
bile acids was performed in Genedata Expressionist [mass values 
(M-H-) and retention time were measured in min, as shown in table 
S3]. Peak areas were normalized to internal standards and sample 
weight (in mg). Calibration of LysoPCs quantities was performed in 
QuantAnalysis (Bruker Daltonics, Bremen, Germany).
Lipid analysis in serum samples
The Bile Acids Kit (Biocrates Life Sciences AG) was used as de-
scribed in the manufacturer’s instructions. Metabolites were ex-
tracted from liver samples by adding H2O/acetonitrile (1:1, v/v) per 
mg of sample, followed by homogenization with a tissue slicer for 
10 min at 30 Hz with four steel beads. Samples were centrifuged at 
1400g for 2 min, and the supernatant was analyzed. The targeted 
analysis was performed by adding 10 l of extracted serum samples 
to the AbsoluteIDQ p180 Kit (Biocrates Life Science AG), following 
the vendor’s instructions (68).
Bomb calorimetry
To analyze intestinal energy absorption, total fecal material was col-
lected over a defined time period (7 days), during which food intake 
and body weight were monitored. The dried sample material was 
homogenized, pressed to a tablet, weighed, and analyzed in dupli-
cate by bomb calorimetry using a GMC bomb calorimeter (IKA 
C7000), following the manufacturer’s instructions.
Quantification of G. lamblia by PCR
Freshly collected fecal samples and standards with 106 to 102 
G. lamblia trophozoites (genome copies) per ml obtained by over-
night culture and verified by counting under the binocular were 
stored at −80°C. DNA isolation was performed using the QIAamp 
DNA Stool Kit (QIAGEN, reference 51504) with one modification 
(step 3, temperature of 95°C instead of 70°C). The DNA concen-
tration was determined on a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific). HotStarTaq Master Mix (10l; QIAGEN), 0.2 l 
of the forward primer Giardia-80F 5′-GACGGCTCAGGACAAC-
GGTT-3′ (69), 0.2 l of the reverse primer Giardia-127R 5′-TTGC-
CAGCGGTGTCCG-3′ (69), 0.2 l of the double-labeled probe 
Giardia-105T FAM-5′-CCCGCGGCGGTCCCTGCTAG-3′-black 
hole quencher 1 (69), 3 l of MgCl2 (from 25 mM substrate; Thermo 
Fisher Scientific), and 4,4 l of RNA/DNA-free H2O were mixed. 
Eighteen microliters of the mix was added to 2 l of DNA. The plate 
was centrifuged at 200g at 4°C for 2 min and treated in the thermo-
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at 60°C, and 30s at 72°C. Fluorescence emitted at 490 nm was recorded. 
The data were analyzed using Bio-Rad CFX Manager software. The 
results were normalized per gram of feces for each sample.
Electron microscopy
Tissues were fixed overnight by immersion in 2% (w/v) glutaraldehyde 
(Polysciences Inc.) in 130 mM cacodylate buffer at pH 7.4 supple-
mented with 2 mM CaCl2 and 10 mM MgCl2. The specimens were 
incubated for 1 hour with 1% (w/v) OsO4 (Polysciences Inc.) in 165 mM 
cacodylate buffer containing 1.5% (w/v) K3[Fe(CH)6], followed by 
0.5% (w/v) uranyl acetate (Agar Scientific) in 50% (v/v) ethanol 
overnight. The samples were embedded in Epon [29.19 g of Epon 
812, 12.66 g of Dodecenylsuccinic anhydride (DDSA), 16.58 g of 
Methylnadicanhydride (MNA), and 0.75 ml of 2,4,6-Tris(dimethyl-
aminomethyl)phenol (DMP30); Serva Electrophoresis GmbH]. After 
Epon hardening at 60°C, ultrathin sections of 50-nm thickness were 
cut and further contrasted with lead citrate and uranyl acetate. Images 
were taken with Morgani or Tecnai G2 T20 electron microscopes 
(FEI) and further processed using ImageJ (version 1.50f).
Flow cytometric analysis
To isolate immune cells, the intestine was cut longitudinally and 
incubated for 2 × 15 min in 2 mM EDTA/Hanks’ balanced salt solu-
tion at 37°C to remove the epithelium. The lamina propria was 
digested in Liberase/deoxyribonuclease (30 g/ml; Roche) for 45 min 
at 37°C and filtered through a 100-m nylon cell strainer to obtain 
a single-cell suspension. Flow cytometric analysis used the follow-
ing gating strategy and antibodies (all purchased from BioLegend). 
Initially, all samples were pregated on CD45+ (CD45-BV510, 30-F11) 
7AAD− (PerCP/7AAD) singlets. Macrophages were subsequently 
identified by MHCIIhi (MHCII-AF488, M5/115.14.2) and CD11c+ 
(CD11c-PECy7, N418), as well as CD64+ (CD64-APC, X54-5/7.1) 
and CD11b+ (CD11b-APC, M1/70); monocytes were subsequently 
identified by Ly6Chi (Ly6C-PerCPCy5.5, HK1.4) and Ly6G− (Ly6G-PE, 
1A8). Polymorphonuclear cells were subsequently identified by Ly6Cint 
and Ly6G+, and mast cells were subsequently identified by MHCII+, 
as well as FceR+ (FceR-PE, MAR-1) and c-kit+ (ckit-APC, 2B8). Data 
were acquired with a BD FACSCanto II and analyzed with FlowJo X.
Primary intestinal epithelial cell isolation and gene 
expression analysis
Isolation of primary intestinal epithelial cells was performed as re-
cently described (70). For gene expression analysis, total RNA was 
extracted from isolated intestinal epithelial cells or liver tissue using 
TRIzol (Invitrogen), and the RNA concentration was determined on 
a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific). 
First-strand cDNA was synthesized from 5 g of total RNA using 
Oligo-dT primers, RevertAid reverse transcriptase, and RiboLock 
ribonuclease inhibitor (Thermo Fisher Scientific). Reverse transcrip-
tion PCR (RT-PCR) was performed using the TaqMan technology 
with an absolute QPCR (quantitative real-time fluorescence PCR) 
ROX mix (Thermo Fisher Scientific); sample cDNA; and the 
TaqMan probes Hprt (Mm00446968-m1), cck (Mm00446170-m1), 
phospholipase A2 (Mm 00448160-m1), fgf15 (Mm00433278-m1), 
cyp7a (Mm00484150-m1), cyp7b (Mm 00484157-m1), cyp27a 
(Mm00470430-m1), and baat (Mm00476075-m1) (Life Technolo-
gies). Results were calculated by the 2-CT method. For data 
analysis, values were normalized to the hprt housekeeping gene 
and presented as fold induction over age-matched controls.
Gut microbiota analysis
For microbiota analysis, dams were co-housed for at least 5 weeks 
before conception and during pregnancy and birth. On the day of 
birth, dams with their litters were separated, and the neonates at 
3 days after birth were either infected with G. lamblia in PBS or treat-
ed with PBS only. Samples for all groups of the microbiota analyses 
were taken from animals of least two litters per cages. Total small 
intestinal and colon tissues were collected at 1 and 4 weeks p.i., re-
spectively. Total genomic DNA from snap-frozen intestinal tissues 
was isolated by repeated bead beating combined with chemical lysis 
and a column-based purification method, as described in detail 
elsewhere (71). Each batch of samples undergoing DNA isolation 
included one negative control consisting of PCR-grade water. Am-
plicon library generation and sequencing were performed accord-
ing to previously published protocols (72, 73). A total of 15,426,330 
V3-V4 reads were generated by sequencing. After trimming, quality 
filtering, removing potential chimeric reads, and demultiplexing 
then removing low abundant operational taxonomic units (OTUs), 
12,912,927 sequences belonging to 177 OTUs were retained for 
downstream analysis. Negative control samples were excluded from 
subsequent analysis. For the remaining samples, which were used to 
further data analysis, the number of sequences per sample ranged 
from 193,055 to 502,246 (median, 313,306). Data demultiplexing, 
length and quality filtering, read pairing, and read clustering into 
OTUs at 97% sequence identity were done via the online Integrated 
Microbial Next-Generation Sequencing platform (74) using default 
settings except for minimum and maximum amplicon length, 
which were set to 300 and 600 base pairs, respectively. Data normal-
ization, diversity, taxonomical binning, and group comparisons 
were performed using the Rhea package (75). Alpha- (observed spe-
cies, Chao1 and Shannon index) and beta-diversity (generalized 
UniFrac) (76) estimates were computed using the R pipeline Rhea 
standard script and settings. Ordination of samples from different 
groups was based on generalized UniFrac, with (dis)similarities 
visualized by Non-metric distance scaling (NMDS). A permutational 
multivariate analysis of variance (PERMANOVA) using distance 
matrices (vegan::adonis) was performed to determine whether each 
group separation was significant, as a whole and in pairs. Alpha- 
diversity parameters and the occurrence of bacterial genera, families, 
and phyla were first tested across all groups using the nonparametric 
Kruskal-Wallis test adjusted for multiple comparisons by the Benjamini- 
Hochberg method. For this analysis, apart from the default settings, 
we used no cutoff for either relative or median abundance, and zeros 
were included in statistics. In case of significance (P < 0.05), pair-
wise group comparison (infected versus control) was performed using 
the Mann-Whitney test corrected for multiple testing, resulting in 
the indicated P values. All taxa with significantly different large in-
testinal abundance according to the Kruskal-Wallis test are reported.
Whole-body adipose tissue imaging
For imaging-based adipose tissue quantification, sacrificed G. lamblia– 
infected (4 weeks p.i.) and age-matched healthy control animals 
were placed into a preclinical x-ray micro–computed tomography 
(CT) scanner (MILabs B.V.) for a total-body CT scan. CT scans 
were performed using an x-ray tube voltage of 65 kV and power of 
0.13 mA. A full gantry rotation acquired 360 projections at an expo-
sure time of 75 ms and an estimated dose of 35 milligray. For image 
analysis, all acquired three-dimensional CT images were recon-
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algorithm (filtered back projection). The adipose tissue–containing 
anatomical regions, which appear hypointense in the CT, were 
segmented using an automated segmentation method that interac-
tively corrected segmentation errors. For all analyses, we used Imalytics 
Preclinical software (77, 78). The volumetric adipose tissue percentage 
was computed as the ratio of total, subcutaneous, visceral, or brown 
adipose tissue volume to the total body volume.
Statistical analysis
Data analyses were performed with GraphPad Prism 7.0 software. 
Statistical analyses were performed for the intergroup variation of 
gut microbiota composition by PERMANOVA, for the analysis of 
positive fecal G. lamblia antigen testing over time (Kaplan-Meier 
curve) with the Mantel-Cox test, for comparisons between two 
groups with the Mann-Whitney U test for nonparametrically dis-
tributed data and for multigroup comparisons with the two-way 
analysis of variance (ANOVA) with Sidak’s or Bonferroni post hoc 
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